Weber Nina C, Frässdorf Jan, Ratajczak Christoph, Grueber Yvonne, Schlack Wolfgang, Hollmann Markus W, Preckel Benedikt
Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Anesth Analg. 2008 Dec;107(6):1807-13. doi: 10.1213/ane.Ob013e31818874bf.
Xenon induces early myocardial preconditioning of the rat heart in vivo, but whether xenon induces late cardioprotection is not known. Cyclooxygenase-2 (COX-2) has been shown to be an important mediator in the signal transduction of myocardial ischemic late preconditioning (i-LPC). We investigated whether xenon induces late preconditioning (Xe-LPC) and whether COX-2 activity and/or expression are involved in mediating this effect.
Anesthetized male Wistar rats were instrumented with a coronary artery occluder. After 7 d of recovery, animals were randomized to 1 of 5 groups each containing 8 animals. The i-LPC group underwent 5 min of coronary occlusion to induce i-LPC. Xe-LPC was achieved by administration of xenon (70 volume%) for 15 min. Additional rats were pretreated with the COX-2 inhibitor NS-398 (5 mg kg(-1) body weight i.p.) with and without Xe-LPC. A group of sham operated animals not undergoing i-LPC or Xe-LPC served as controls (Con). After 24 h, all animals were anesthetized and underwent 25 min of myocardial ischemia induced by tightening of the coronary artery occluder followed by 2 h of reperfusion. Myocardial infarct size was assessed by triphenyltetrazolium chloride staining. In additional experiments, hearts were excised at different time points after preconditioning to investigate COX-2 mRNA and protein expression by polymerase chain reaction and infrared Western blot, respectively.
Both i-LPC and Xe-LPC reduced myocardial infarct size (% of the area at risk) compared with Con (i-LPC: 29 +/- 7%; Xe-LPC 31 +/- 8%, both P < 0.05 vs Con 64 +/- 6%). NS-398 abolished the cardioprotective effect of Xe-LPC (61 +/- 6%, P < 0.05 vs Xe-LPC). COX-2 mRNA and protein expression was only increased in the i-LPC group, but not in the Xe-LPC group.
Xenon induces late myocardial preconditioning that is abolished by functional blockade of COX-2 activity. In contrast to i-LPC, Xe-LPC did not lead to an increased expression of COX-2 mRNA and protein. These data suggest differences in COX-2 regulation in i-LPC and Xe-LPC.
氙可在体内诱导大鼠心脏早期心肌预处理,但氙是否能诱导延迟性心脏保护尚不清楚。环氧合酶-2(COX-2)已被证明是心肌缺血延迟预处理(i-LPC)信号转导中的重要介质。我们研究了氙是否能诱导延迟预处理(Xe-LPC)以及COX-2活性和/或表达是否参与介导这种效应。
将麻醉的雄性Wistar大鼠安装冠状动脉阻塞器。恢复7天后,将动物随机分为5组,每组8只。i-LPC组进行5分钟的冠状动脉阻塞以诱导i-LPC。通过给予氙(70体积%)15分钟来实现Xe-LPC。另外的大鼠在有或无Xe-LPC的情况下用COX-2抑制剂NS-398(5mg·kg⁻¹体重腹腔注射)进行预处理。一组未进行i-LPC或Xe-LPC的假手术动物作为对照(Con)。24小时后,所有动物麻醉,通过收紧冠状动脉阻塞器诱导25分钟心肌缺血,随后再灌注2小时。通过氯化三苯基四氮唑染色评估心肌梗死面积。在另外的实验中,在预处理后的不同时间点取出心脏,分别通过聚合酶链反应和红外免疫印迹法研究COX-2 mRNA和蛋白表达。
与Con组相比,i-LPC和Xe-LPC均减小了心肌梗死面积(危险区域面积的百分比)(i-LPC:29±7%;Xe-LPC 31±8%,两者与Con组64±6%相比P<0.05)。NS-398消除了Xe-LPC的心脏保护作用(61±6%,与Xe-LPC组相比P<0.05)。COX-2 mRNA和蛋白表达仅在i-LPC组中增加,而在Xe-LPC组中未增加。
氙可诱导延迟性心肌预处理,COX-2活性的功能阻断可消除这种预处理。与i-LPC不同,Xe-LPC不会导致COX-2 mRNA和蛋白表达增加。这些数据表明i-LPC和Xe-LPC中COX-2调节存在差异。